VA
PRVB

VR Adviser’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

VR Adviser’s Portfolio PRVB Stock Details PRVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,118,653
Closed -$11.8M – 32
2022
Q4 		$11.8M Hold
1,118,653
– – 1.99% 17
2022
Q3 		$5.03M Hold
1,118,653
– – 0.78% 23
2022
Q2 		$4.47M Hold
1,118,653
– – 0.88% 22
2022
Q1 		$8.19M Buy
+1,118,653
New +$6.69M 1.33% 18
2021
Q3 		– Sell
-2,902,744
Closed -$24.5M – 34
2021
Q2 		$24.5M Buy
+2,902,744
New +$23.4M 2.97% 14

Other funds holding PRVB

SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

VR Adviser's PRVB Position: Q1 2023 in Review

VR Adviser sold out of Provention Bio, Inc. Common Stock (PRVB) in Q1 2023, closing a stake of 1,118,653 shares — an estimated $11.8M sold.

VR Adviser first reported a position in PRVB in Q2 2021 and held it in 5 quarters. The position peaked at $24.5M in Q2 2021. 182 funds tracked by Wall St. Rank hold PRVB as of Q1 2023.

  • VR Adviser reported no remaining Provention Bio, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • VR Adviser sold 1,118,653 Provention Bio, Inc. Common Stock shares in Q1 2023, an estimated $11.8M.
  • VR Adviser first reported a position in Provention Bio, Inc. Common Stock in Q2 2021 and held it in 5 quarters.
  • VR Adviser's Provention Bio, Inc. Common Stock position peaked at $24.5M in Q2 2021.
  • 182 funds tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q1 2023.

Based on VR Adviser's 13F filing for Q1 2023, filed 15 May 2023.